Mayo Clinic offers CAR T-cell therapy for lymphoma
Volume 7, Issue 1, 2018
Regenerative immunotherapy is becoming one of the most promising new areas of cancer treatment.
Yi Lin, M.D., Ph.D.
The Mayo Clinic Cancer Center in Minnesota is one of just 16 centers selected nationally to provide a type of chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with B-cell non-Hodgkin's lymphoma who have relapsed or haven't responded to two or more lines of treatment.
This type of CAR T-cell therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma, and high-grade B-cell lymphoma.
"CAR T-cell therapy is a cell-based regenerative immunotherapy, and it is one of the most promising new areas of cancer treatment," said Yi Lin, M.D., Ph.D., a hematologist and chair of the Cellular Therapeutics Cross-Disciplinary Group at Mayo Clinic's campus in Rochester, Minnesota. "This therapy uses genetically modified versions of a patient's own immune cells to fight the cancer. I like to describe these modified T cells as super robocops designed to seek out and destroy a particular cancer."
CAR T-cell therapy begins by collecting a patient's white blood cells (T cells) and sending them to a central manufacturing facility, where they are genetically modified to direct them against a patient's cancer. Once processed, the CAR T cells are frozen and sent back to the hospital for IV infusion back into the patient.
Patients first undergo a short chemotherapy regimen to condition their body to receive the CAR T cells. Once infused, the CAR T cells proliferate inside the body and begin to recognize and attack cancer cells.
Mayo Clinic has successfully participated in CAR T-cell clinical trials with Kite Pharma, a Gilead Sciences Inc. subsidiary, and other manufacturers of T-cell therapies. "As one of the first treatment centers in the country, patients will be under the care of a team of experts trained in CAR T-cell therapy for cancer treatment," Dr. Lin said.
Patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma, and high-grade B-cell lymphoma who have relapsed or haven't responded to two or more lines of treatment and are interested in CAR T-cell therapy can contact the Mayo Clinic Hematology Appointment office at 507-284-5363 to request an appointment for evaluation and assessment for eligibility for CAR T-cell therapy.